Exhibit 99.1

           TRANSGENOMIC APPOINTS PRESIDENT AND CHIEF EXECUTIVE OFFICER

     OMAHA, Neb., July 12 /PRNewswire-FirstCall/ -- Transgenomic Inc. (Nasdaq:
TBIO) announced today that its Board of Directors has elected Craig Tuttle to
the position of President and Chief Executive Officer effective immediately. Mr.
Tuttle will be based at the Company's headquarters in Omaha and succeed interim
Chief Executive Officer, Mike Summers, who will continue as the Company's Chief
Financial Officer.

     Craig Tuttle has over 25 years of general management, sales and marketing
and research and development experience in medical diagnostic and biotechnology
companies. He was formerly the President and COO of Duke Scientific, a Northern
California specialty chemistry manufacturer. He led the sale of Duke Scientific
to Fisher Healthcare in 2005. Prior to that, he was the President of Applied
Biotech, Inc., the manufacturer of the market leading home pregnancy tests. He
ran Seradyn, Inc., a specialty chemical and diagnostic test manufacturer, where
he took the company from losing $2 million a year to a net profit of $3 million
in just over one year. Mr. Tuttle has also held management positions with
Boehringer Mannheim, Bayer Healthcare and Cetus Corporation. When at Cetus, he
was involved in the very first instrument platforms for PCR. In addition to his
senior management experience, he has led R&D teams for large product development
projects. His largest product development project was the $100 million joint
venture program between Bayer and Shell Oil. Mr. Tuttle earned a B.S. in
Biochemistry from UCLA, an M.S. in Biochemistry from the University of Colorado
and an M.B.A from St. Mary's College.

     Mr. Tuttle commented, "I am very enthusiastic about the opportunity to lead
Transgenomic and aggressively execute its business plan. While challenges exist,
the Company has a solid foundation of highly qualified professionals, dynamic
customers and leading-edge technologies that will allow us to take full
advantage of recent trends in molecular research and diagnostics."

     In making the announcement, the Company's founder and Chairman of the
Board, Collin D'Silva, stated, "We are very pleased to have Craig aboard
following a thorough search process. Not only will his extensive experience
allow him to hit the ground running, he will add industry-specific management
expertise helpful in driving our growing involvement in the diagnostic products
and services markets."

     About Transgenomic

     Transgenomic is a global biotechnology company that provides unique
systems, products, discovery and laboratory testing services to the academic and
medical research, clinical and pharmaceutical markets for automated high
sensitivity genetic variation and mutation analysis in the fields of
pharmacogenomics and personalized medicine. This is accomplished through their
offerings of Wave(TM) DHPLC systems, reagents, consumables and assay kits,
Hanabi automated cytogenetics systems, and Transgenomic Discovery and CLIA Lab
Services. To date there have been over 1,200 Wave systems installed in over 600
customer sites in over 35 countries and approximately 1,500 publications
utilizing Transgenomic products or services. Transgenomic Discovery and Lab
Services utilize their technology and expertise to provide a menu of mutation
scanning tests for over 700 cancer-associated genes and more than 60 validated
diagnostic tests to meet the needs of pharmaceutical and biotech companies,
research and clinical laboratories, physicians and patients. For more
information about the innovative systems, products and services offered by
Transgenomic, please visit: www.transgenomic.com.



     Transgenomic Cautionary Statements

     Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include, but
are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the Company to grow
its involvement in the diagnostic products and services markets. The known
risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly, the company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking statements,
unless required by law.

SOURCE  Transgenomic Inc.
    -0-                             07/12/2006
    /CONTACT:  Mike Summers of Transgenomic, Inc., +1-402-452-5446/
    /Web site:  http://www.transgenomic.com /